982 related articles for article (PubMed ID: 16968503)
1. Levofloxacin-based triple therapy in first-line treatment for Helicobacter pylori eradication.
Nista EC; Candelli M; Zocco MA; Cremonini F; Ojetti V; Finizio R; Spada C; Cammarota G; Gasbarrini G; Gasbarrini A
Am J Gastroenterol; 2006 Sep; 101(9):1985-90. PubMed ID: 16968503
[TBL] [Abstract][Full Text] [Related]
2. Clarithromycin-amoxycillin-containing triple therapy: a valid empirical first-line treatment for Helicobacter pylori eradication in Hong Kong?
Hung IF; Chan P; Leung S; Chan FS; Hsu A; But D; Seto WK; Wong SY; Chan CK; Gu Q; Tong TS; Cheung TK; Chu KM; Wong BC
Helicobacter; 2009 Dec; 14(6):505-11. PubMed ID: 19889067
[TBL] [Abstract][Full Text] [Related]
3. 7-day triple therapy of Helicobacter pylori infection with levofloxacin, amoxicillin, and high-dose esomeprazole in patients with known antimicrobial sensitivity.
Antos D; Schneider-Brachert W; Bästlein E; Hänel C; Haferland C; Buchner M; Meier E; Trump F; Stolte M; Lehn N; Bayerdörffer E
Helicobacter; 2006 Feb; 11(1):39-45. PubMed ID: 16423088
[TBL] [Abstract][Full Text] [Related]
4. Comparison of levofloxacin-containing sequential and standard triple therapies for the eradication of Helicobacter pylori.
Polat Z; Kadayifci A; Kantarcioglu M; Ozcan A; Emer O; Uygun A
Eur J Intern Med; 2012 Mar; 23(2):165-8. PubMed ID: 22284248
[TBL] [Abstract][Full Text] [Related]
5. [Levofloxacin-based triple therapy for first-line Helicobacter pylori eradication treatment: a multi-central, randomized, controlled clinical study].
Cheng H; Hu FL; Zhang GX; Shi RH; Du YQ; Li ZS; Han W; Li YQ; Wu QD; Qian KD
Zhonghua Yi Xue Za Zhi; 2010 Jan; 90(2):79-82. PubMed ID: 20356486
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of levofloxacin-based rescue therapy for Helicobacter pylori infection after standard triple therapy: a randomized controlled trial.
Kuo CH; Hu HM; Kuo FC; Hsu PI; Chen A; Yu FJ; Tsai PY; Wu IC; Wang SW; Li CJ; Weng BC; Chang LL; Jan CM; Wang WM; Wu DC
J Antimicrob Chemother; 2009 May; 63(5):1017-24. PubMed ID: 19246508
[TBL] [Abstract][Full Text] [Related]
7. Second-line levofloxacin-based triple schemes for Helicobacter pylori eradication.
Di Caro S; Franceschi F; Mariani A; Thompson F; Raimondo D; Masci E; Testoni A; La Rocca E; Gasbarrini A
Dig Liver Dis; 2009 Jul; 41(7):480-5. PubMed ID: 18974025
[TBL] [Abstract][Full Text] [Related]
8. Role of the preliminary susceptibility testing for initial and after failed therapy of Helicobacter pylori infection with levofloxacin, amoxicillin, and esomeprazole.
Marzio L; Coraggio D; Capodicasa S; Grossi L; Cappello G
Helicobacter; 2006 Aug; 11(4):237-42. PubMed ID: 16882326
[TBL] [Abstract][Full Text] [Related]
9. Comparison of sequential and standard triple-drug regimen for Helicobacter pylori eradication: a 14-day, open-label, randomized, prospective, parallel-arm study in adult patients with nonulcer dyspepsia.
Uygun A; Kadayifci A; Yesilova Z; Safali M; Ilgan S; Karaeren N
Clin Ther; 2008 Mar; 30(3):528-34. PubMed ID: 18405790
[TBL] [Abstract][Full Text] [Related]
10. Helicobacter pylori eradication: a randomized prospective study of triple therapy versus triple therapy plus lactoferrin and probiotics.
de Bortoli N; Leonardi G; Ciancia E; Merlo A; Bellini M; Costa F; Mumolo MG; Ricchiuti A; Cristiani F; Santi S; Rossi M; Marchi S
Am J Gastroenterol; 2007 May; 102(5):951-6. PubMed ID: 17313499
[TBL] [Abstract][Full Text] [Related]
11. Clinical trial: clarithromycin vs. levofloxacin in first-line triple and sequential regimens for Helicobacter pylori eradication.
Molina-Infante J; Perez-Gallardo B; Fernandez-Bermejo M; Hernandez-Alonso M; Vinagre G; Dueñas C; Mateos-Rodriguez JM; Gonzalez-Garcia G; Abadia EG; Gisbert JP
Aliment Pharmacol Ther; 2010 May; 31(10):1077-84. PubMed ID: 20180787
[TBL] [Abstract][Full Text] [Related]
12. Preoperative versus postoperative Helicobacter pylori eradication therapy in gastric cancer patients: a randomized trial.
Kim CG; Song HJ; Kook MC; Hong EK; Park S; Lee JY; Lee JH; Ryu KW; Kim YW; Bae JM; Choi IJ
Am J Gastroenterol; 2008 Jan; 103(1):48-54. PubMed ID: 17714557
[TBL] [Abstract][Full Text] [Related]
13. Nonbismuth quadruple "concomitant" therapy versus standard triple therapy, both of the duration of 10 days, for first-line H. pylori eradication: a randomized trial.
Georgopoulos S; Papastergiou V; Xirouchakis E; Laoudi F; Lisgos P; Spiliadi C; Papantoniou N; Karatapanis S
J Clin Gastroenterol; 2013 Mar; 47(3):228-32. PubMed ID: 22858517
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of Levofloxacin, Clarithromycin and Esomeprazol as first line triple therapy for Helicobacter pylori eradication in Middle East. Prospective, randomized, blind, comparative, multicenter study.
Assem M; El Azab G; Rasheed MA; Abdelfatah M; Shastery M
Eur J Intern Med; 2010 Aug; 21(4):310-4. PubMed ID: 20603042
[TBL] [Abstract][Full Text] [Related]
15. Nonbismuth quadruple (concomitant) therapy: empirical and tailored efficacy versus standard triple therapy for clarithromycin-susceptible Helicobacter pylori and versus sequential therapy for clarithromycin-resistant strains.
Molina-Infante J; Pazos-Pacheco C; Vinagre-Rodriguez G; Perez-Gallardo B; Dueñas-Sadornil C; Hernandez-Alonso M; Gonzalez-Garcia G; Mateos-Rodriguez JM; Fernandez-Bermejo M; Gisbert JP
Helicobacter; 2012 Aug; 17(4):269-76. PubMed ID: 22759326
[TBL] [Abstract][Full Text] [Related]
16. Levofloxacin-containing triple and sequential therapy or standard sequential therapy as the first line treatment for Helicobacter pylori eradication in China.
Qian J; Ye F; Zhang J; Yang YM; Tu HM; Jiang Q; Shang L; Pan XL; Shi RH; Zhang GX
Helicobacter; 2012 Dec; 17(6):478-85. PubMed ID: 23067317
[TBL] [Abstract][Full Text] [Related]
17. Second-line rescue therapy with levofloxacin after H. pylori treatment failure: a Spanish multicenter study of 300 patients.
Gisbert JP; Bermejo F; Castro-Fernández M; Pérez-Aisa A; Fernández-Bermejo M; Tomas A; Barrio J; Bory F; Almela P; Sánchez-Pobre P; Cosme A; Ortiz V; Niño P; Khorrami S; Benito LM; Carneros JA; Lamas E; Modolell I; Franco A; Ortuño J; Rodrigo L; García-Durán F; O'Callaghan E; Ponce J; Valer MP; Calvet X;
Am J Gastroenterol; 2008 Jan; 103(1):71-6. PubMed ID: 17764498
[TBL] [Abstract][Full Text] [Related]
18. Randomized comparison of two rescue therapies for Helicobacter pylori infection.
Wu DC; Hsu PI; Chen A; Lai KH; Tsay FW; Wu CJ; Lo GH; Wu JY; Wu IC; Wang WM; Tseng HH
Eur J Clin Invest; 2006 Nov; 36(11):803-9. PubMed ID: 17032348
[TBL] [Abstract][Full Text] [Related]
19. Ranitidine bismuth citrate-based triple therapies as a second-line therapy for Helicobacter pylori in Turkish patients.
Köksal AS; Parlak E; Filik L; Yolcu OF; Odemiş B; Ulker A; Saşmaz N; Ozden A; Sahin B
J Gastroenterol Hepatol; 2005 Apr; 20(4):637-42. PubMed ID: 15836716
[TBL] [Abstract][Full Text] [Related]
20. Cumulative H. pylori eradication rates in clinical practice by adopting first and second-line regimens proposed by the Maastricht III consensus and a third-line empirical regimen.
Rokkas T; Sechopoulos P; Robotis I; Margantinis G; Pistiolas D
Am J Gastroenterol; 2009 Jan; 104(1):21-5. PubMed ID: 19098844
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
